VCYT Veracyte, Inc.

25.04USD-2.07%Mkt Cap: 2.02B USDP/E: 16.26

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap2.02B USD
Enterprise Value1.73B USD
Revenue (TTM)581.78M USD
Gross Profit362.53M USD
Net Income (TTM)66.35M USD
Revenue/Share7.29 USD
Last Price25.04 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees755
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)16.26
P/E (Forward)16.10
PEG—
EV/EBITDA15.91
EV/Revenue2.98
P/S3.47
P/B1.41
EPS (TTM)1.54 USD
EPS (Forward)1.56 USD
52W Range
21.918% of range60.91
52W High60.91 USD
52W Low21.91 USD
Profitability
Gross Margin70.10%
Oper. Margin15.02%
EBITDA Margin18.73%
Profit Margin12.83%
ROE5.07%
ROA4.72%
ROIC8.13%
ROCE5.82%
Growth
Revenue Growth15.10%
Earnings Growth58.30%
Cash Flow & Leverage
Operating CF136.31M USD
CapEx (TTM)9.68M USD
FCF Margin19.06%
FCF Yield5.49%
Net Debt-329.80M USD
Net Debt/EBITDA-3.03
Net Debt/FCF-2.97
Balance Sheet
Debt/Equity0.03
Current Ratio5.56
Quick Ratio5.08
Book Value/Sh17.77 USD
Cash/Share4.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)41.60 USD
Upside (mean)+66.1%
Target Range30.00 USD – 60.00 USD
30.00+66.1% to mean60.00
# Analysts10
Ownership
Shares Out.80.70M
Float80.19M
Insiders0.53%
Institutions118.62%
Short Interest
Short Ratio8.1d
Short % Float13.99%
Short % Out.11.85%
Shares Short9.56M
Short (prev mo.)10.18M
Technical
SMA 5041.79 (-40.1%)
SMA 20042.31 (-40.8%)
Beta1.96
S&P 52W Chg12.08%
Avg Vol (30d)2.35M
Avg Vol (10d)4.43M
Technical Indicators
RSI (14)30.9
MACD-5.8316
MACD Signal-4.8155
MACD Hist.-1.0161
BB Upper62.15 USD
BB Middle36.09 USD
BB Lower10.02 USD
BB Width144.45%
ATR (14)2.970 USD
Vol Ratio (20d)0.64x

About Veracyte (NASDAQ: VCYT)

›

Veracyte (NASDAQ: VCYT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 755 employees.

The shares were at 25.04 USD on 19 November 2026, down 45.6% over 52 weeks. Its 52-week range is 21.91 USD to 60.91 USD: the price is 58.9% below the high and 14.3% above the low.

At a market capitalisation of 2.02B USD, it trades at 16.3 times trailing earnings and 16.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 55% for VCYT.

Veracyte reports return on equity of 5.1%, an operating margin of 15.0% and revenue up 15.1% year over year.

It holds more cash than debt, a net cash position of 329.80M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 41.60 USD is 66.1% above the current price. The next earnings report is expected on 24 February 2027.